DGX vs. RPRX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DGX and RPRX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DGX | RPRX |
|---|---|---|
| Company Name | Quest Diagnostics Incorporated | Royalty Pharma plc |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 20.50 billion USD | 22.25 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | December 17, 1996 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DGX and RPRX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DGX | RPRX |
|---|---|---|
| 5-Day Price Return | 3.53% | 1.85% |
| 13-Week Price Return | 3.34% | 6.49% |
| 26-Week Price Return | 4.38% | 17.68% |
| 52-Week Price Return | 18.00% | 45.32% |
| Month-to-Date Return | 4.75% | 2.66% |
| Year-to-Date Return | 22.17% | 51.08% |
| 10-Day Avg. Volume | 1.12M | 4.97M |
| 3-Month Avg. Volume | 1.03M | 3.77M |
| 3-Month Volatility | 20.35% | 27.28% |
| Beta | 0.63 | 0.43 |
Profitability
Return on Equity (TTM)
DGX
13.75%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
DGX’s Return on Equity of 13.75% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
RPRX
11.59%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RPRX’s Return on Equity of 11.59% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
DGX
8.93%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 8.93% places DGX in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
RPRX
32.55%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 32.55% places RPRX in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DGX
14.11%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 14.11% places DGX in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RPRX
65.22%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
RPRX’s Operating Profit Margin of 65.22% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | DGX | RPRX |
|---|---|---|
| Return on Equity (TTM) | 13.75% | 11.59% |
| Return on Assets (TTM) | 6.05% | 4.16% |
| Net Profit Margin (TTM) | 8.93% | 32.55% |
| Operating Profit Margin (TTM) | 14.11% | 65.22% |
| Gross Profit Margin (TTM) | 33.47% | -- |
Financial Strength
Current Ratio (MRQ)
DGX
1.13
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
DGX’s Current Ratio of 1.13 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
RPRX
3.48
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RPRX’s Current Ratio of 3.48 is in the upper quartile for the Pharmaceuticals industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
DGX
0.78
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
DGX’s Debt-to-Equity Ratio of 0.78 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
RPRX
1.39
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
RPRX’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.39. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
DGX
7.42
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
DGX’s Interest Coverage Ratio of 7.42 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
RPRX
4.70
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
RPRX’s Interest Coverage Ratio of 4.70 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | DGX | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 1.13 | 3.48 |
| Quick Ratio (MRQ) | 0.88 | 3.48 |
| Debt-to-Equity Ratio (MRQ) | 0.78 | 1.39 |
| Interest Coverage Ratio (TTM) | 7.42 | 4.70 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DGX
1.74%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Yield of 1.74% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
RPRX
1.69%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RPRX’s Dividend Yield of 1.69% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
DGX
35.81%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Payout Ratio of 35.81% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
RPRX
49.36%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RPRX’s Dividend Payout Ratio of 49.36% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DGX | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 1.74% | 1.69% |
| Dividend Payout Ratio (TTM) | 35.81% | 49.36% |
Valuation
Price-to-Earnings Ratio (TTM)
DGX
20.57
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
DGX’s P/E Ratio of 20.57 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RPRX
29.16
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
A P/E Ratio of 29.16 places RPRX in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
DGX
1.84
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
DGX’s P/S Ratio of 1.84 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RPRX
9.49
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
With a P/S Ratio of 9.49, RPRX trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
DGX
2.94
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
DGX’s P/B Ratio of 2.94 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RPRX
3.21
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RPRX’s P/B Ratio of 3.21 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | DGX | RPRX |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.57 | 29.16 |
| Price-to-Sales Ratio (TTM) | 1.84 | 9.49 |
| Price-to-Book Ratio (MRQ) | 2.94 | 3.21 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.31 | 18.52 |